Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 7, 2021

ABECMA (idecabtagene vicleucel suspension)

LENGTH OF AUTHORIZATION: Date of service

ADMINISTRATION: Hospital inpatient or outpatient setting

REVIEW CRITERIA:

- Patient must be ≥ 18 years of age.
- Patient must have a diagnosis of relapsed or refractory multiple myeloma.
- Patient must have tried and failed at least 4 lines of prior therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

DOSING:

- Dosing of Abecma is based on the number of chimeric antigen receptor (CAR)-positive T cells
- The recommended dose range is 300 to 460 x 10^6 CAR-positive T cells

*Because of the risk of Cytokine Release Syndrome (CRS), neurological toxicities, Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLM/MAS), and prolonged cytopenia, ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMA REMS. Further information is available at www.AbecmaREMS.com or 1-888-423-5436.